Attending ESGCT next week? Check out our posters featured during the Wednesday Poster Session from 1:30 p.m. – 3:30 p.m. CET. For more information on the presentations, read here: bit.ly/3TOmo4z. #ESGCT2026 #ESGCTHamburg2026 #invivo #cardiovasculardisease

#NEWS: Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference. Read the press release for details: bit.ly/4B4N1CT. #ESGCT2026 #Guggenheim #invivo

Yesterday, we announced approval to initiate our Phase 1/2 Strive™ study of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia. Read the press release here: bit.ly/4jKSqZt. #cardiovasculardisease #HeFH #geneediting #clinicaltrials

#NEWS: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia. Read the press release for details: bit.ly/4jKSqZt. #geneediting #HeFH #cardiovasculardisease #clinicaltrials

Last week, Editas participated in fireside chats at the Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference, sharing updates on EDIT-401 and connecting with the wider healthcare and investment communities. Listen here: bit.ly/4r3c2d4. #invivo

Tomorrow, we’ll be participating in a fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET. Tune in here: bit.ly/4dbvZbP. #geneediting #cardiovasculardisease #firesidechat

We’re thrilled to welcome Dan Ory, M.D., as Chief Medical Officer at Editas Medicine. Dr. Ory brings decades of experience in cardiovascular disease, genetic medicines, and clinical development as we advance EDIT-401 toward the clinic. Read more: bit.ly/4y1Mwb3 #invivo

#NEWS: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer. Read the press release for details: bit.ly/4y1Mwb3. #geneediting #cardiovasculardisease #leadership

On Tuesday, we’ll be participating in a fireside chat at the Wells Fargo Healthcare Conference at 4:30 p.m. ET. Tune in here: bit.ly/4i4kbvA. #invivo #cardiovasculardisease #firesidechat

#NEWS Editas Medicine to Participate in Upcoming Investor Conferences. Read the press release here: bit.ly/4yhw1as. #geneediting #cardiovasculardisease #invivo

Our President & CEO Gilmore O’Neill discusses the evolution of gene editing, the potential of in vivo approaches, and the opportunity to develop durable, potentially one-time therapies for patients with serious diseases: Read here: bit.ly/4qnl7Nr. #biotech #leadership

It was a pleasure to attend the @thecsanz 2026 Scientific Meeting in Sydney, connecting with experts advancing cardiovascular research. We’re grateful to share our work as we continue advancing EDIT-401 toward the clinic Read our e-poster here: bit.ly/4z7RlQZ. #CSANZ2026

Earlier this week, Editas Medicine announced second quarter 2026 results and business updates. Read the full press release here: bit.ly/4wdJgr4. #genediting #biotech #cardiovasculardisease #earnings

Welcome Patrick Ellinor, M.D., Ph.D., to the Editas Medicine Board of Directors. A recognized leader in cardiovascular medicine and genetics, Dr. Ellinor brings extensive experience as we advance EDIT-401 toward the clinic: bit.ly/3RVJ5Tk. #cardiovasculardisease #invivo

#NEWS Editas Medicine Announces Second Quarter 2026 Results and Business Updates. Read the full press release here: bit.ly/4hQCOTo #cardiovasculardisease #invivo #earnings

#NEWS Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. Read the full press release here: bit.ly/4fVpSJu #geneediting #cardiovasculardisease #boardofdirectors

Thank you to everyone who joined us last week at Cell & Gene Therapy World Asia 2026. It was a pleasure connecting with colleagues from across the cell and gene therapy community and sharing insights on the value of early CMC integration. #CGTAsia2026 #CGTWA2026 #CMC #biotech

It was great to participate in this year’s European Congress on Biotechnology. We enjoyed connecting with researchers, innovators, and industry leaders from across the biotechnology community to discuss the future of genetic medicines. #ECB2026 #biotechnology #geneediting #invivo

Last week, Team Editas participated in the annual J.P. Morgan Corporate Challenge. It was a great opportunity to connect with colleagues and celebrate teamwork beyond the workplace. Thank you to everyone who participated and represented Editas Medicine! #JPMCorporateChallenge

Next week, we'll present at Cell & Gene Therapy World Asia 2026 with our session, "Designing for Development: The Role of Early CMC Integration in Product Lifecycle Success." See you in Singapore! #CGTAsia2026 #CGTWA2026 #CellAndGeneTherapy #CMC #Biomanufacturing